NewsEvents

Your Yourlocation: Home > Combination therapy with tiotropium bromide(136310-93-5) and inhaled glucocorticoid / long-acting beta2 agonist (ICS/ LABA)

The Selective Retinoic Acid Receptor Agonist Therapy for Emphysema (TESRA) study was a 2-year, randomized, double-blind, placebo-controlled, phase II multicenter trial of 492 patients with emphysema. All patients received tiotropium bromide(136310-93-5) and inhaled glucocorticoid / long-acting beta2 agonist (ICS / LABA) combination therapy. The primary outcome was the extent of FEV1-to-baseline change at 2 years.

As a result, all baseline characteristics were well matched in both groups, with 71% and 70% of patients completing a 2-year placebo and palovarotene treatment, respectively. In addition to mild mucosal and skin events (69% vs 38%), patients were more tolerated of palovarotene. In the palovarotene group (29%), the number of acute exacerbations of chronic obstructive pulmonary disease (COPD) was reduced by 19% compared with placebo (36%). In patients with lower pulmonary emphysema, the lung function (DLco and FEV1) improved significantly in the palovarotene group compared with the placebo group.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved